Posted inClinical Updates Hematology-Oncology news
Dynamic Genetic and Nongenetic RAS-Pathway Activation Drives Resistance to FLT3 and BCL2 Inhibitor Therapy in AML
This review synthesizes cutting-edge findings on how genetic and nongenetic RAS-pathway activation mediates resistance to combined FLT3 and BCL2 inhibition in acute myeloid leukemia, highlighting implications for treatment strategies and biomarker development.